SteadyMed, which is developing a proprietary pump system for the treatment of PAH and pain, raised $40 million by offering 4.7 million shares at $8.50, below the range of $12 to $14. SteadyMed will list on the NASDAQ under the symbol STDY. Wells Fargo Securities and RBC Capital Markets acted as joint bookrunners on the deal.
